BiomX Presenting at Three Upcoming Investor Conferences
2022 Aegis Virtual Conference on February 24, 2022
Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022
Oppenheimer & Co. 32nd Annual Virtual Healthcare Conference on March 17, 2022
NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the 2022 Aegis Virtual Conference on February 24, 2022, the Chardan 4th Annual Microbiome Medicines Summit on March 1, 2022 and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17, 2022.
|
2022 Aegis Virtual Conference – February 23-25, 2022 |
||
|
|
|
|
|
Date & Time: |
Thursday, March 24, 2:30 PM EST |
|
|
Presenter: |
Jonathan Solomon |
|
|
Conference registration: |
||
|
Chardan 4th Annual Microbiome Medicines Summit – March 1, 2022 |
||
|
|
|
|
|
Date & Time: |
Tuesday, March 1, 8:30 AM EST |
|
|
Presenter: Conference registration: |
Jonathon Solomon |
|
|
Oppenheimer & Co. 32nd Annual Healthcare Conference – March 15-17, 2022 |
||
|
|
|
|
|
Date & Time: |
Thursday, March 17, 2:00 PM EST |
|
|
Presenter: |
Jonathan Solomon |
|
|
Conference registration: |
||
Live webcasts of presentations will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.
About BiomX Inc.
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220224005117/en/
BiomX Contacts
Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com
BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com
Source: BiomX Inc.
Released February 24, 2022